Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2012, Article ID 125458, 14 pages
http://dx.doi.org/10.1155/2012/125458
Review Article

Role of Adipokines in Atherosclerosis: Interferences with Cardiovascular Complications in Rheumatic Diseases

1SERGAS, Santiago University Clinical Hospital and NEIRID Lab (NeuroEndocrine Interaction in Rheumatology and Inflammatory Diseases), Institute of Medical Research (IDIS), Building C, Level-2, 15706 Santiago de Compostela, Spain
2Division of Rheumatology, Fundación Jiménez Diaz, 2-28040 Madrid, Spain
3SERGAS, Santiago University Clinical Hospital and Division of Orthopaedics Surgery and Traumatology, 15706 Santiago de Compostela, Spain
4SERGAS, Santiago University Clinical Hospital and Laboratory of Genetics in Rheumatic Diseases, Institute of Medical Research (IDIS), Building C, Level-2, 15706 Santiago de Compostela, Spain
5SERGAS, Santiago University Clinical Hospital and Research Laboratory 7 (Molecular and Cellular Cardiology), Institute of Medical Research (IDIS), 15706 Santiago de Compostela, Spain

Received 6 June 2012; Accepted 19 June 2012

Academic Editor: Miguel A. González-Gay

Copyright © 2012 Morena Scotece et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Patients with rheumatic diseases have an increased risk of mortality by cardiovascular events. In fact, several rheumatic diseases such as rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, and ankylosing spondylitis are associated with a higher prevalence of cardiovascular diseases (CVDs). Although traditional cardiovascular risk factors have been involved in the pathogenesis of cardiovascular diseases in rheumatic patients, these alterations do not completely explain the enhanced cardiovascular risk in this population. Obesity and its pathologic alteration of fat mass and dysfunction, due to an altered pattern of secretion of proinflammatory adipokines, could be one of the links between cardiovascular and rheumatic diseases. Indeed, the incidence of CVDs is augmented in obese individuals with rheumatic disorders. Thus, in this paper we explore in detail the relationships among adipokines, rheumatic diseases, and cardiovascular complications by giving to the reader a holistic vision and several suggestions for future perspectives and potential clinical implications.